FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Breast Cancer
Relevance: Medium-Low
Quality of Writing: Medium
Research Timeline: Animal Studies
Article : Promising drug for cancer treatment begins clinical trials
Relevance: Medium-Low
Quality of Writing: Medium
Research Timeline: Animal Studies
Most relevant for: People with solid tumors.
Researchers at City of Hope are testing a new type of cancer treatment drug. When tested in animals and cells taken from human cancers, this new drug prevented the growth of many types of cancer. Initial clinical trials in people have just started. (Posted 9/7/23)
Este artículo está disponible en español.
Read More
Topic : Sex and intimacy after breast cancer
Most relevant for: People with breast cancer or metastatic breast cancer in sexual or intimate relationships and their partners
A breast cancer diagnosis and treatment can affect relationships with romantic partners. This review highlights two studies that looked at how people with breast cancer and their partners are affected, how they cope, how best to communicate with each other and how to talk with healthcare providers about concerns related to cancer and sexuality. (Posted 8/8/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Progestin birth control may slightly increase breast cancer risk
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People who are using or have recently used birth control containing only the hormone progestin
Different types of birth control carry different cancer risks. Birth control using the hormone progestin slightly increases the risk of breast cancer during use and for a few years after use. (Posted 7/10/23)
Este artículo está disponible en español.
Read More
Study : Breast cancer disparities among the LGBTQ+ community
Most relevant for: People belonging to the LGBTQ+ community
This study looked at differences in breast cancer treatment outcomes among people from the LGBTQ+ community. (Posted 6/28/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Guideline : What is breast density and why does it matter?
Relevance: Medium-High
Most relevant for: People who have mammograms
New FDA guidelines for mammograms will go into effect by September 2024. Current FDA guidance requires hospitals and breast centers to give people information about their breast density with their mammogram results. By September 2024, mammogram providers will need to relay to patients who have dense breast that they should discuss the need for additional imaging. This article provides an overview of what breast density means and why it matters. (Posted 6/8/23)
Este artículo está disponible en español.
Read More
Relevance: Medium
Topic : Impact of new laws on cancer treatment during pregnancy
Relevance: Medium
Most relevant for: People who have cancer who are pregnant
The U.S. Supreme Court ruled in 2022 that abortion is no longer a protected right under the Constitution. This landmark decision leaves regulation of abortion to the states. Cancer treatment during pregnancy may now be impacted in states that have abortion bans or limitations. (Posted 5/31/23)
Este artículo está disponible en español.
Read More
Article : A food lover’s decision to remove her stomach highlights difficult decisions around cancer risk
Most relevant for: People with a CDH1 mutation or a family history of stomach cancer
National Public Radio reporter Sáša Woodruff shares her story of learning about her CDH1 mutation and making a decision about risk-reducing surgery. Mutations in the CDH1 gene significantly increase a person’s risk of stomach and breast cancers. Woodruff’s personal essay describes the psychological challenge of making decisions about risk-reducing surgeries and draws attention to a lesser-known mutation linked to hereditary cancer. (Posted 5/17/23)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Breast cancer outcomes improved with CDK4/6 inhibitor treatment
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People with HR-positive HER2-negative advanced breast cancer
A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)
Este artículo está disponible en español.
Read More
Relevance: Medium
Strength of Science: Medium
Research Timeline: Animal Studies
Study : Weight may affect breast cancer risk in women with an inherited BRCA mutation
Relevance: Medium
Strength of Science: Medium
Research Timeline: Animal Studies
Most relevant for: People with an inherited mutation in BRCA1 or BRCA2 concerned about their breast cancer risk
A study that looked at normal breast cells from women with an inherited BRCA mutation found more DNA damage among women who were overweight (based on a measurement known as body mass index) than those who were not overweight. The results suggest that maintaining a lower weight may reduce breast cancer among this high-risk population. (Posted 3/30/23)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : New oral drug treatment for some advanced breast cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with HR-positive, HER2-negative advanced breast cancer
The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)
Este artículo está disponible en español.
Read More
Search XRAY studies and Articles
This Portal Sponsored By:
